Danny Rischin
Impact in
- Otorhinolaryngology top 0.02%
- Head and Neck Cancer Studies
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Head and Neck Cancer Studies 130
- Oncology 96
- Cancer Immunotherapy and Biomarkers 29
- Cancer Treatment and Pharmacology 13
- Co-authors
- June F. Corry (74 shared papers)Lester J. Peters (28 shared papers)Rodney J. Hicks (40 shared papers)Richard Fisher (23 shared papers)Benjamin Solomon (37 shared papers)Richard J. Young (27 shared papers)Sandro Virgilio Porceddu (34 shared papers)Andrea Feyereislova (6 shared papers)
- Journals
- Annals of Oncology (41 papers)Journal of Clinical Oncology (33 papers)International Journal of Radiation Oncology*Biology*Physics (33 papers)Head & Neck (15 papers)Oral Oncology (14 papers)
- Partner nations
- AustraliaUnited StatesCanada
In The Last Decade
Danny Rischin
343 papers receiving 22.2k citations
Danny Rischin's Hit Papers
Peers
Comparison fields: 5 of 135
- Otorhinolaryngology 5.8k
- Oncology 5.9k
- Pulmonary and Respiratory Medicine 4k
- Cancer Research 1.4k
- Radiation 823
Countries citing papers authored by Danny Rischin
This map shows the geographic impact of Danny Rischin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danny Rischin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danny Rischin more than expected).
Fields of papers citing papers by Danny Rischin
This network shows the impact of papers produced by Danny Rischin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danny Rischin. The network helps show where Danny Rischin may publish in the future.
Co-authors
The 25 scholars most cited alongside Danny Rischin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 360 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2003 | 2507 |
| 2 | Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study Hit paper breakdown → | 2019 | 2497 |
| 3 | PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma Hit paper breakdown → | 2018 | 1097 |
| 4 | Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types Hit paper breakdown → | 2002 | 729 |
| 5 | Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02 Hit paper breakdown → | 2010 | 672 |
| 6 | Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial Hit paper breakdown → | 2010 | 636 |
| 7 | 2006 | 469 | |
| 8 | Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial Hit paper breakdown → | 2020 | 371 |
| 9 | 2003 | 369 | |
| 10 | Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments Hit paper breakdown → | 2018 | 365 |
| 11 | Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study Hit paper breakdown → | 2022 | 342 |
| 12 | Survival with Cemiplimab in Recurrent Cervical Cancer Hit paper breakdown → | 2022 | 322 |
| 13 | Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group Hit paper breakdown → | 2010 | 319 |
| 14 | 2009 | 311 | |
| 15 | 2005 | 255 | |
| 16 | 2018 | 249 | |
| 17 | 1996 | 230 | |
| 18 | 2011 | 225 | |
| 19 | Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma Hit paper breakdown → | 2022 | 225 |
| 20 | 2004 | 218 |
About Danny Rischin
Danny Rischin is a scholar working on Otorhinolaryngology, Oncology, Epidemiology, Reproductive Medicine and Pulmonary and Respiratory Medicine, having authored 360 papers that have together received 23k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (130 papers), Nonmelanoma Skin Cancer Studies (45 papers), Cancer Immunotherapy and Biomarkers (29 papers), Ovarian cancer diagnosis and treatment (21 papers), Lung Cancer Diagnosis and Treatment (20 papers), Endometrial and Cervical Cancer Treatments (14 papers), Cancer Treatment and Pharmacology (13 papers) and Medical Imaging Techniques and Applications (12 papers). The work is most often cited by research in Otorhinolaryngology (5.8k citations), Oncology (5.9k citations), Pulmonary and Respiratory Medicine (4k citations), Cancer Research (1.4k citations) and Radiation (823 citations). Danny Rischin has collaborated with scholars based in Australia, United States and Canada. Frequent co-authors include June F. Corry, Lester J. Peters, Rodney J. Hicks, Richard Fisher, Benjamin Solomon, Richard J. Young, Sandro Virgilio Porceddu, Andrea Feyereislova, Steven D. Averbuch and José Baselga. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Head & Neck and Oral Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.